Haemonetics Corporation  

(Public, NYSE:HAE)   Watch this stock  
Find more results for HAE
+0.56 (1.77%)
Nov 25 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.50 - 32.11
52 week 29.70 - 45.42
Open 31.58
Vol / Avg. 165,718.00/287,673.00
Mkt cap 1.60B
P/E 64.51
Div/yield     -
EPS 0.50
Shares 50.72M
Beta 0.80
Inst. own 105%
Jan 27, 2016
Q3 2016 Haemonetics Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 19, 2015
Haemonetics Corp at Jefferies Autumn Global Healthcare Conference - Webcast
Nov 4, 2015
Q2 2016 Haemonetics Corp Earnings Release
Nov 4, 2015
Q2 2016 Haemonetics Corp Earnings Call - Webcast
Sep 17, 2015
Haemonetics Corp at Morgan Stanley Healthcare Conference
Sep 9, 2015
Haemonetics Corp at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 5.85% 1.86%
Operating margin 8.73% 4.45%
EBITD margin - 20.77%
Return on average assets 3.63% 1.13%
Return on average equity 6.58% 2.03%
Employees 3,383 -
CDP Score - -


BRAINTREE, MA 02184-2412
United States - Map
+1-781-8487100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Haemonetics Corporation is a healthcare company, which provides blood management solutions to its customers. The Company's portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma, Blood Center, Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan.

Officers and directors

Ronald G. Gelbman Interim Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Christopher J. Lindop Chief Financial Officer, Executive Vice President - Business Development
Age: 57
Bio & Compensation  - Reuters
Thomas McCurdy President - Global Plasma
Bio & Compensation  - Reuters
Byron Selman President - Global Markets
Bio & Compensation  - Reuters
Kent J. Davies Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
David D. Helsel Executive Vice President - Global Manufacturing
Age: 51
Bio & Compensation  - Reuters
Jonathan White Chief Science and Technology Officer
Age: 55
Bio & Compensation  - Reuters
Susan Hanlon Chief Accounting Officer, Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Brian R. Burns Vice President,global quality and regulatory affairs
Age: 51
Bio & Compensation  - Reuters
Sandra Jesse Vice President, Chief Legal Officer
Age: 62
Bio & Compensation  - Reuters